

Date: 21st May, 2026

To,
The Bombay Stock Exchange Limited
P. J. Towers
Dalal Street, Fort
Mumbai 400 001

Scrip Code: 544091

ISIN: INE0Q1R01012

Sub: Investor Presentation H2 & FY 2025-26

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed Investors Presentation of M/s Qualitek Labs Limited (“**the Company**”) on the financial results and operational performance for the H2 and FY 2026.

The aforesaid information shall also be made available on the Company’s website at: [Qualitek-Lab Investors-PPT_FY26-200526_final.pdf](#)

You are requested to kindly take the above information on record.

Thanking you

Yours Sincerely

For Qualitek Labs Limited

Mohit Kumar
Company Secretary cum Compliance Officer
ACS 38142



Qualitek Labs
Delivering Business Confidence

Investors Presentation

H2 & FY2025-26

20th May 2026



Disclaimer

This Presentation is intended to provide the general information about the Company's business as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be construed as a recommendation to subscribe/purchase the shares of the company. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain forward-looking statements. These statements are based on current estimates, expectations, forecasts and assumptions that may be subject to certain risks and uncertainties. The actual outcomes and results may differ materially from those statements. Important factors that could cause actual results to differ materially from our estimates include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other foreign currencies, changes in interest rates, changes in applicable laws and regulations, increasing competition, changes in political conditions in India or any other country and changes in foreign exchange regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

Executive Summary

- FY 2025-26 was the year Qualitek Labs delivered commitment of ₹125 Crore Consolidated Revenue — a four-fold increase over FY24, and the strongest set of results since we listed on the BSE in January 2024.
- A humble beginning in 2018 by a team of Corporate Professionals by acquiring an Automobile Testing Lab in Pune, formerly established by a reputed MNC.
- SME IPO in January 2024 at an issue price of ₹100/- per share. Listed on BSE at ₹200/- per share on Day 1 of listing. Current m-Cap stands at over ₹400 Crore.
- Acquired Interstellar Testing Centre in 2024-25 to strengthen footprint into Lifesciences business viz. Pharmaceuticals, Food & Feed, Nutraceuticals, Cosmetics, etc.
- Currently having a pan-India network of 10 owned Labs and 6 PPP Labs with a strong team of 1200+ colleagues, covering the entire scope of TIC services with a highly diversified portfolio.



CONSOLIDATED RESULTS

Half-year and Financial Year ended 31 March 2026



Key Financial Metrics: H2 FY26 (Consolidated)

Revenue

₹ 70.3 Cr

▲ +56% vs LY;
▲ +30% vs H1

EBITDA

₹ 18.1 Cr

▲ +102% vs LY;
▲ +61% vs H1

EBITDA Margin

26%

▲ +6% vs LY;
▲ +5% vs H1

Net Profit

₹ 9.8 Cr

▲ +143% vs LY;
▲ +106% vs H1

Net Profit Margin

14%

▲ +5% vs LY;
▲ +5% vs H1

Earnings Per Share

₹ 8.7

▲ +114% vs LY
▲ +85% vs LY

Results Summary: H2 FY26 (Consolidated)

Revenue from Operations:

The company reported consolidated revenue of **₹70.3 Cr** in H2 FY26, reflecting a robust **56% YoY growth** over ₹45.2 Cr in H2 FY25, and **30% increase sequentially** compared to ₹54.2 Cr in H1 FY26.


EBITDA:

Consolidated EBITDA for H2 FY26 stands at **₹18.1 Cr**, registering strong **102% YoY growth** over ₹8.9 Cr in H2 FY25, and **61% increase sequentially** compared to ₹11.2 Cr in H1 FY26. Consolidated EBITDA margin is **26% in H2 FY26**, improved from **20% in H2 FY25**, and **21% in H1 FY26**.


PAT:

Consolidated PAT for H2 FY26 is **₹9.8 Cr**, delivering **143% YoY growth** over ₹4.0 Cr in H2 FY25, and **106% increase on sequential basis** compared to ₹4.8 Cr in H1 FY26. Consolidated PAT margin for H2 FY26 is **14%**, improving by 5% compared to **9% in both H2 FY25 and H1 FY26**.


REVENUE(Rs Cr.)



EBITDA(Rs Cr.)



PAT(Rs Cr.)



Income Statement: H2 FY26 (Consolidated)

Particulars (INR Crore)	H1-26	H2-26	H-o-H
Revenue from operations	54.24	70.27	30%
Material cost & Direct Expenses	8.01	8.62	
Gross Profit	46.23	61.65	33%
<i>Gross Margin</i>	85%	88%	
Employee benefit expenses	20.22	24.53	
Other expenses	14.79	19.06	
EBITDA	11.22	18.06	61%
<i>EBITDA Margin</i>	21%	26%	
Depreciation and amortization	2.95	3.73	
EBIT	8.27	14.33	73%
Finance cost	1.92	2.88	
Other income	0.08	0.44	
Profit before tax	6.43	11.89	85%
Tax expense	1.66	2.06	
Profit after tax	4.77	9.83	106%
PAT Margin	9%	14%	

Note: Consolidation applicable from H1-26 onwards. Hence comparative figures for H2-25 are not available

Key Financial Metrics: FY26 (Consolidated)

Revenue

₹ 124.5 Cr

▲ +77% vs LY

EBITDA

₹ 29.3 Cr

▲ +80% vs LY

EBITDA Margin

24%

▲ +1% vs LY

Net Profit

₹ 14.6 Cr

▲ +90% vs LY

Net Profit Margin

12%

▲ +1% vs LY

Earnings Per Share

₹ 13.4

▲ +90% vs LY

Results Summary: FY26 (Consolidated)

Revenue from Operations:

The company reported consolidated revenue of ₹124.5 Cr in FY26, reflecting a robust **77% YoY growth** over ₹70.2 Cr in FY25.


EBITDA:

Consolidated EBITDA for FY26 stands at ₹29.3 Cr, registering **80% YoY growth** over ₹16.3 Cr in FY25. Consolidated EBITDA margin is **24% in FY26**, improved 1% from **23% in FY25**.


PAT:

Consolidated PAT for FY26 is ₹14.6 Cr, delivering strong **90% YoY growth** over ₹7.7 Cr in FY25. Consolidated PAT margin is **12% in FY26**, improved 1% from **11% in FY25**.


Revenue(Rs Cr.)



EBITDA(Rs Cr.)



PAT(Rs Cr.)



Financials Over The Years: Income Statement


Particulars (INR Crore)	FY23	FY24	FY25	FY26	YoY	CAGR
Revenue from operations	19.13	29.18	70.23	124.52	77%	87%
Material Cost & Direct Expense	4.24	5.61	10.20	16.64		
Gross Profit	14.89	23.57	60.03	107.88	80%	94%
Gross Margin	78%	81%	85%	87%		
Employee benefit expenses	3.65	6.04	24.13	44.74		
Other expenses	5.93	9.46	19.65	33.85		
EBITDA	5.31	8.07	16.25	29.29	80%	77%
EBITDA Margin	28%	28%	23%	24%		
Depreciation and amortization	0.84	1.39	4.25	6.69		
EBIT	4.47	6.68	12.00	22.60	88%	72%
Finance cost	0.69	0.90	2.09	4.81		
Other income	0.21	0.08	0.51	0.53		
Profit before tax	3.99	5.86	10.42	18.32	76%	66%
Tax expense	0.99	1.47	2.74	3.72		
Profit after tax	3.00	4.39	7.68	14.60	90%	69%
PAT Margin	16%	15%	11%	12%		

Financials Over The Years: Balance Sheet


Particulars (INR Crore)	FY23	FY24	FY25	FY26
Non-current assets				
PPE & intangible assets	28.52	37.11	74.95	119.47
Goodwill	0	0	33.04	78.12
Other non current assets	2.48	1.77	7.32	14.6
Total non-current assets	31.00	38.88	115.31	212.19
Current assets				
Inventories	0	0	2.65	3.18
Trade receivables	5.82	7.85	28.86	42.14
Cash and bank balances	0.35	1.77	5.17	6.05
Other current assets	2.42	2.09	5.93	7.38
Total current assets	8.59	11.71	42.61	58.75
Total assets	39.59	50.59	157.92	270.94
Equity				
Equity share capital	5.41	7.37	9.98	11.65
Reserves & surplus	4.49	25.08	76.83	140.77
Minority Interest	0	0	5.97	0
Total equity	9.90	32.45	92.78	152.42
Non-current liabilities				
Long term borrowings	10.34	10.17	30.86	60.12
Deffered tax liabilities	0.59	0.86	0.74	0.60
Long term provisions	0.07	0.23	0.96	1.55
Total non-current liabilities	11.00	11.26	32.56	62.27
Current liabilities				
Short term borrowings	13.11	2.08	19.12	32.86
Trade payables	3.67	2.38	7.28	9.39
Short term Provisions	0.02	0.11	0.59	0.92
Other current liabilities	1.89	2.31	5.59	13.08
Total current liabilities	18.69	6.88	32.58	56.25
Total equity and liabilities	39.59	50.59	157.92	270.94

Financial KPIs Over the Years


REVENUE(Rs Cr.)




EBITDA(Rs Cr.)




PAT(Rs Cr.)




ROE



ROCE



DEBT-EQUITY RATIO





Standalone RESULTS

Half-year and Financial Year ended 31 March 2026



Key Financial Metrics: H2 FY26 (Standalone)

Revenue

₹ 38.6 Cr

▲ +55% vs LY;
▲ +33% vs H1

EBITDA

₹ 10.0 Cr

▲ +39% vs LY;
▲ +53% vs H1

EBITDA Margin

26%

▲ -3% vs LY;
▲ +3% vs H1

Net Profit

₹ 5.2 Cr

▲ +45% vs LY;
▲ +85% vs H1

Net Profit Margin

13%

▲ -1% vs LY;
▲ +4% vs H1

Earnings Per Share

₹ 4.6

▲ +21% vs LY
▲ +66% vs H1

Results Summary: H2 FY26 (Standalone)

Revenue from Operations:

The company reported standalone revenue of **₹38.6 Cr** in H2 FY26, reflecting a robust **55% YoY growth** over ₹24.9 Cr in H2 FY25, and **33% increase sequentially** compared to ₹29.0 Cr in H1 FY26.


EBITDA:

Standalone EBITDA for H2 FY26 stands at **₹10.0 Cr**, registering **39% YoY growth** over ₹7.2 Cr in H2 FY25, and **53% increase sequentially** compared to ₹6.5 Cr in H1 FY26. Standalone EBITDA margin is **26% in H2 FY26**, compared to **29% in H2 FY25**, and **23% in H1 FY26**.


Profit After Tax (PAT)

Standalone PAT for H2 FY26 is **₹5.2 Cr**, delivering **45% YoY growth** over ₹3.6 Cr in H2 FY25, and **85% increase on sequential basis** compared to ₹2.8 Cr in H1 FY26. Standalone PAT margin for H2 FY26 is **13%**, compared to **14% in H2 FY25**, and **10% in H1 FY26**.


REVENUE(Rs Cr.)



EBITDA(Rs Cr.)



PAT(Rs Cr.)



Key Financial Metrics: FY26 (Standalone)

Revenue

₹ 67.6 Cr

▲ +47% vs LY

EBITDA

₹ 16.6 Cr

▲ +42% vs LY

EBITDA Margin

24%

▲ -1% vs LY

Net Profit

₹ 8.0 Cr

▲ +51% vs LY

Net Profit Margin

12%

▲ +0.3% vs LY

Earnings Per Share

₹ 7.3

▲ +23% vs LY

Results Summary: FY26 (Standalone)

Revenue from Operations:

The company reported consolidated revenue of ₹67.6 Cr in FY26, registering a robust **47% YoY growth** over ₹45.9 Cr in FY25.


EBITDA:

Standalone EBITDA for FY26 stands at ₹16.6 Cr, delivering **42% YoY growth** over ₹11.7 Cr in FY25. Standalone EBITDA margin is **24% in FY26**, compared to **25% in FY25**.


Profit After Tax (PAT)

Standalone PAT for FY26 is ₹8.0 Cr, delivering strong **51% YoY growth** over ₹5.3 Cr in FY25. Standalone PAT margin for FY26 is **12%**, compared to **11.5% in FY25**.


Revenue(Rs Cr.)



EBITDA(Rs Cr.)



PAT(Rs Cr.)



Qualitek Labs at a Glance



Qualitek Labs
Delivering Business Confidence

Infrastructure

From 25K Sq. Ft. in 2018
to 290K Sq. Ft. in 2026

8+



Years of Expertise

350+



Collection Centres

15+



**National & International
Accreditations & Approvals**

1200+



Employees
(including 450 Scientists,
363 Field Staff, 180 Support
Staff, 7 NABL Assessors)

Digital



**Complete Automated
Operation with
Traceability**

Diversified



**Automotive, Minerals,
Energy, Medical Device,
Pharma, Environment,
Electricals & Electronics**

10



Own Laboratories

6



**Govt Labs
operated in PPP
mode**

>5 Million




Tests per year

5000+



**Customers (Govts,
International &
National Leaders)**


Qualitek Labs Growth Journey



Drug Control Administration
Department of Health and Family Welfare, Government of Odisha



Nationwide Operations



Location	Services
Pune – Unit –I & II	Automotive Testing (EV battery, electrical systems, vibration, durability, corrosion, emission testing); Defence Testing; Electrical & Electronics Testing; Mines & Minerals Testing; Infrastructure & Building Materials Testing; Pharma Packaging & Medical Device Safety Testing
Noida	Electrical & Electronics Testing (advanced lab with VOC testing); Automotive Testing; Mines & Minerals Testing; Medical Equipment Testing
Bhubaneshwar Unit –I & II	Minerals & Metals Testing (Coal, Iron Ore, Chrome, etc.); Food Testing; Environment & Water Testing; Drugs & Pharma Testing; Infrastructure & Building Materials Testing
Paradip	Mines & Minerals Testing (onsite, port cabin facilities for coal & ores)
Panchkula	Drugs & Pharma Testing; Ayurvedic & Herbal Testing; Food Testing; Cattle Feed Testing; Environment & Water Testing; Infrastructure & Building Materials Testing; Cosmetics Testing; Medical Equipment Testing
Chennai	Food Testing; Environment & Water Testing; Cattle Feed Testing; Cosmetics Testing
Bangalore	Pharmaceuticals & Cosmetics Testing for USFDA and EU regulatory markets
Mumbai	Food Testing; Cattle Feed Testing, Environment & Water Testing;

International Collaborations



STC - Hong Kong for Automotive, VOC, and Electrical & Electronics Testing

Prime Certification - Dubai for Inspections, Certifications, Technology Transfers and Geo-technical surveys.

GALAB - Germany for Food testing and **HCS - Netherlands** for export Homologation



QAV - Malaysia for Automotive, Electricals and Electronics testing
RID-China for Food & Cosmetics testing.

ITC - Czech Republic for Automotive analytical services and **IMAT UV - Malaysia** for Automotive & Emissions Testing

Bureau Veritas – France and China for Auto. & Emissions testing

ITC – Japan for EMI/EMC and Electricals & Electronics testing

Key Growth Drivers

Transport, Defence & Mechanical

40–45%
*of Consolidated
Revenue*

- Strong presence in West and Northern regions
- Geographic expansion in South region in FY27

Pharma

15–20%
*of Consolidated
Revenue*

- Strong presence in North region
- Expansion underway in South; West expansion in next 2 years
- Acquisition of USFDA lab underway, commercial by June 2026

Food & Feed

25–30%
*of Consolidated
Revenue*

- Pan-India presence across North, South, West and East regions
- Expansion on-going in all regions — Capacity & Scope
- Hyderabad acquisition expected to complete by June 2026

Emerging Business

**Growth
Verticals**

- Inspection, Audit & Certifications
- Medical Devices • Packaging Material
- Energy • Oil & Gas • Consumer Products
- Fumigation Testing

Strategic Initiatives & Capex Allocation Strategy

Strategic Initiatives FY2025-26

- **Capex Light Business Module**
 - Inspection, Audit & Certification
 - Environment & Sustainability
 - Mineral Labs
- Building New Capability in Existing Business
- Cross Selling across Regions
- Geographic Expansion
- Lab Process Outsourcing
- Infrastructure Building




Strategic Initiatives FY2026-27

- Hub and Spoke Module Lab Network across India
- Digitalization
- Technology Solution
- Margin Growth
- Selective Acquisitions In India
- Overseas Business Expansion
- **Specialized Services in Core Business**
 - EMI/EMC
 - VOC
 - USFDA Accredited Lab in Pharma

Capex Investments: FY2025-26

- Invested INR 51.3 Cr in Capex during FY 2025-26.
- Acquisition of Food testing lab in Mumbai
- Operationalized 2nd lab in Bhubaneswar
- Capacity expansion of Pharma and Food labs in Panchkula and Chennai
- New scope addition in Transport and Defence segments
- Setting-up VOC testing facility in Noida
- **Acquired land & building in Barwala, Panchkula for future expansion ★**



Capex Strategy: FY2026-27

- Plan of INR 63 Crore Capex in FY2026-27.
- M&A opportunities across Pharma, Food and Electricals & Electronics segments
- Further capacity expansion of Food labs in Mumbai, Chennai and Bhubaneswar
- Accreditation for Inspections, Audit, Certification and Fumigation business
- Geographic expansions in Transport and Minerals segments
- New Revenue Streams — Set-up EMI/EMC in Pune and Analytical lab in Noida

Way Forward

FY27 Expectations

Revenue:

Deliver **35–40% revenue growth**, driven by geographic expansion and new segment additions.

EBITDA:

We expect to Expand **EBITDA margins by 25-26%**, reflecting operational leverage and cost discipline.

PAT:

Achieve **PAT margins of 15–17%**, underpinned by improved profitability across core business segments

Medium Term Goal

- Be One of the Leading Global lab by 2031-32.

STRATEGY TO ACHIEVE ASPIRATIONS

01

Geographic expansion in automotive sector in South India

02

Strengthen M&A activity in Pharmaceuticals and Food segments

03

Further geographic expansion in Food testing — West and East regions

04

Cross functional synergies and KAM strategy

05

Strengthen Lab Process Outsourcing (LPO) — Pharma, Food, Oil & Gas, Semi-conductors, Environment

06

Initiate Audit, Certification & Fumigation towards 'Low-capex' business model

07

Operational excellence to optimize cost and improve profitability

08

Retain and recruit best talent to strengthen operational capabilities

09

Capability development for new products in Food and Minerals segment

Industries We Are Servicing

Automotive



Defense



Electricals & Electronics



Minerals & Natural Resources



Pharmaceuticals



Cosmetics



Ayurvedic and Herbal Products



Food & Feed



Environmental & Water Studies



Infrastructure and Building Materials



Medical Equipments



Inspections, Audits & Consultancy



Automotive Testing Services

Locations: Pune | Noida

Specialisation

- EV Battery Testing
- Environmental Testing for components and Vehicles
- On-Board Electrical Systems (OBE) Testing
- IP Testing and Tightness Evaluation
- Shock and Vibration Testing
- Chemical, Mechanical and Metallurgical Testing
- Corrosion Testing
- Fatigue and Durability Testing
- Vehicle Interior Emission Testing

Accreditations



OEM's Served

SKODA

MARUTI SUZUKI



DAIMLER



Volkswagen



ROYAL
ENFIELD



JAGUAR
HYUNDAI



FCA

FIAT CHRYSLER AUTOMOBILES



Homologation & Certification Consultation

Our Objectives

- **Vehicle & Component Certification**
Providing consultancy for certification through government-recognized testing authorities.
- **Export Homologation Guidance**
Helping international clients align with Indian regulations for seamless export certification.
- **Standards Harmonization**
Consulting on the alignment of Indian and international homologation standards.

Case Study

Zoomlion (China) – Export homologation consultancy for **off-road vehicle certification**.

Key Clients

ZOOMLION

ramp ✖ GROUP



FICOSA

LUMAX



Defence Testing Services

Locations: Pune



Specialisation

JSS 55555 & MIL 810 Standard

- Vibration Test
- High Temperature
- Damp Heat
- Low Temperature
- Rapid Temperature (Thermal Shock)
- Corrosion
- Bump
- Mold Growth/Fungus
- Tropical Exposure
- Drip
- Environmental Stress Screening
- Burn-In
- Dust
- Altitude
- Driving Rain


Accreditations



Key Clients



BHARAT FORGE



Electricals & Electronics Testing Services

Locations: Pune | Noida



Specialisation

- Electrical Equipment Testing
- Advanced Electronics Testing
- Comprehensive Battery Testing
- VOC Testing and Oduor Analysis
- ELV Vehicle Testing

Accreditations



IS302
IEC60695
JSS55555

SAE
JIS
GSO

FIMS
UNECE
IS13252

IEC62368
IS616
MIL810

Key Clients

Mahindra
ELECTRIC

BAJAJ
Bajaj Electricals Ltd.
Inspiring Trust

UNO MINDA
DRIVING THE NEW

fiecm
LIGHT UP THE WORLD

SEDEMAC

SIGMA
ENGINEERED SOLUTIONS

PHILIPS

Huf

signify

VOLTAIRA

varroc
EXCELLENCE

SPARK MINDA
Powered by Passion

ANTOLIN

ANTOLIN



Minerals, Metals and Natural Resources Testing Services

Locations: Pune | Noida | Paradeep | Bhubaneshwar



In-house & On-site Labs - Porta Cabin

- Complete Quality Testing & Analysis like GCV, Moisture ultimate analysis etc.
- Onsite Teams at mines for bulk sampling, onsite sample preparation & loading / unloading control.
- Total Moisture & Ash content determination.
- Fuel Handling & Blending Services.
- Stock audits & Physical Verifications

Ores & Minerals

Coke/coke
Iron Ore
Chrome Ore
Limestone
Quartz
Bauxite

Ferroalloys & Metal

Silicomanganese
Ferromanganese
Ferrochrome
Ferrosilicon
Ferrovandium
Ferromolybdenum Steel
Pig Iron/Cast Iron
Sponge Iron

Building Materials

Fly Ash
Cement
Clinker
Granulated Slag

Others

Refractories
Clay
Feldspar
Fluorspar
Gypsum
Slag
Pyroxenite/Olivin
Sand Ramming Mass

Accreditations



Key Clients



Drugs & Pharmaceuticals Testing Services

Locations: Panchkula | Bhubaneshwar



Specialisation

- Our Specialisation
- Nitrosamine & NDSRI testing
- Genotoxic impurities (GTI) evaluations
- Elemental impurities studies as per ICH Q3D
- Stability indicating analytical method development & validations as per ICH and Leachable studies
- Cleaning method validations
- EG and DEG in cough syrups
- Impurity identification and quantitation by LC-MS/MS and GC-MS/MS
- Residual solvents testing by GC-HS ETO, ECH and EG residue in medical devices
- Multimedia dissolution profiling studies Microbiology testing

Accreditations



Key Clients



Cosmetics Testing Services

Locations: Panchkula | Chennai




Specialisation

- Preservative Efficacy Test
- BET and Sterility Testing
- Microbial Limit Tests
- Herbal Identification Acute Toxicity Testing
- Skin Irritation Testing
- Residual Formaldehyde Assessment
- Thermal Stability and Shelf-Life Studies
- Quality Parameters
- Heavy Metals Analysis
- Phthalates Testing
- 1,4-Dioxane Detection
- Residual Solvents Analysis
- Aflatoxins Testing
- Pesticide Residue Analysis
- Bisphenol A (BPA) Testing
- Preservative Analysis (Parabens, Sulphates)

Accreditations

EC/1223/2009
Cosmetic License, Haryana

Key Clients



Ayurvedic & Herbal Testing Services

Locations: Panchkula

Specialisation

- Physico-Chemical Analysis API Identification
- Heavy Metal Testing
- Microbiological Analysis
- Pesticide Residue Analysis Residual Solvent Testing
- Aflatoxin & Pesticide
- GC Profile Analysis
- Residue Analysis
- Phytochemical Analysis
- Preservative Efficacy Testing
- Shelf-Life Studies

Accreditations



MINISTRY OF
AYUSH



Key Clients



Food Testing Services

Locations: Pune | Chennai | Bhubaneshwar



Specialisation

- Nutritional Label Testing
- Allergen Testing
- Packaging Material Testing
- Residual Pesticides and Antibiotics
- Accelerated Shelf-Life Testing
- Real-Time Shelf Testing
- Migration Testing

Accreditations



Key Clients



TATA CONSUMER PRODUCTS



Cattle Feed Testing Services

Locations: Panchkula | Chennai



Specialisation

- Nutritional Value
- Testing Contaminant Analysis
- Stability Testing

Accreditations



Key Clients



Pradeshik Cooperative Dairy Federation, Uttar Pradesh
प्रादेशिक कोआपरेटिव डेयरी फेडरेशन, उत्तर प्रदेश



Environment & Water Testing Services

Locations: Panchkula | Chennai | Bhubaneshwar

Specialisation in Environment

- Wastewater Testing : Effluent Treatment Plants, Sewage Treatment Plants
- Soil Testing: Soil Fertility Testing, Soil Health Cards, Construction Soil Testing
- Air Testing: Stack Monitoring, Ambient Air Quality Testing Migration Testing
- Sound Testing Sediment Testing LUX

Specialisation in Water

- Potable Water Testing
- Construction Water Testing
- Swimming Pool Water Testing
- RO Dialysis Water
- Surface and Groundwater
- RO compatibility checks
- Chlorine testing

Accreditations



Key Clients



Infrastructure & Building Material Testing Services

Locations: Panchkula | Bhubaneshwar



Specialisation

- Cement & Concrete Testing
- Soil & Geotechnical Testing
- Aggregate & Road Construction Material Testing
- Non-Destructive Testing (NDT)
- Metals & Structural Materials Testing
- Pipes, Tiles, and Coatings Testing
- Oil Testing & Oil Analysis

Accreditations



Key Clients



Medical Equipment Testing Services

Locations: Panchkula | Noida

Specialisation

- Bacterial Endotoxin Test
- Sterility Testing
- Bend Test
- Test
- Pull-Out Test Penetrability Test
- Breakage

Accreditations



Key Clients



॥ सर्वे सन्तु निरामयाः ॥



PHILIPS
Healthcare

SIEMENS

DEVON

xlo

Meril

Inspection, Audits & Consultancy

3rd Party Inspection Services (AQL Level Based)

- Mineral & Metals
- Food & Agri Commodities
- Textiles & Hardgoods
- Road Traffic Survey
- Pharmaceuticals
- NDT Services
- Market Survey

Consultancy for In house Lab Set ups (Turnkey Solutions)

- ISO 17025, Layout planning & Equipment selection
- Method training & Correlation
- ISO 17025 accreditation consultancy

Consultancy on Consumer Products compliance requirements for export to

- US (CPSC, CALPROP65, CPSIA etc)
- Europe (REACH, SVHC, EC 2010/11)
- Rest of the world etc.

Platform Building in Last 7 years



Particulars	2020	2022	2024	2026	CAGR
Revenue	4	12	29	125	77%
Employees	25	87	165	1200+	91%
No. of Labs	3	4	6	16	32%
No. of Business Line	4	5	7	15	25%
Lab Area (K Sq. Ft)	45	95	160	290	36%
Cumulative Acquisitions	1	2	4	6	



Qualitek Labs
Delivering Business Confidence

THANK YOU